When it comes to assessing the outlook for drugmakers, investors really only care about the pipeline of new drugs. After all, existing drugs eventually lose patent protection, and when that happens, a large hole in the income statement… Read More
David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk. David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech. David Stermanon
Analyst Articles
I've found a rare bargain in a pricey market... Read More
What I’m about to show you will probably be new. Over the past few months, my staff and I have read hundreds of newspapers, blogs and financial articles. As shocking as it may sound, we’ve never seen one mention of what I’m about to… Read More
Stock markets jumped after the unemployment rate rose on hopes that the Fed will continue pumping up the… Read More
As soon as I met Ryan O’Connor, I knew I wanted to get him on my team. He’s an investing junkie like me, and we clicked immediately. Turns out it’s all in his family… His grandfather was an old poker buddy of… Read More
Warning: The Rebound May Be Over For Big Pharma
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a… Read More
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a year later. A decade later, Big Pharma’s “patent cliff” was still a key concern, and this index remained far from its previous highs. Yet in recent quarters, Big Pharma has come back with a vengeance, as shares have moved back to the levels seen all those years ago. Credit goes to several factors, most notably the absence of any new imminent blockbuster-drug patent expirations, and an industrywide focus on shareholder-friendly moves such as share… Read More
Warning: The Rebound May Be Over For Big Pharma
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a… Read More
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a year later. A decade later, Big Pharma’s “patent cliff” was still a key concern, and this index remained far from its previous highs. Yet in recent quarters, Big Pharma has come back with a vengeance, as shares have moved back to the levels seen all those years ago. Credit goes to several factors, most notably the absence of any new imminent blockbuster-drug patent expirations, and an industrywide focus on shareholder-friendly moves such as share… Read More
Warning: The Rebound May Be Over For Big Pharma
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a… Read More
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a year later. A decade later, Big Pharma’s “patent cliff” was still a key concern, and this index remained far from its previous highs. Yet in recent quarters, Big Pharma has come back with a vengeance, as shares have moved back to the levels seen all those years ago. Credit goes to several factors, most notably the absence of any new imminent blockbuster-drug patent expirations, and an industrywide focus on shareholder-friendly moves such as share… Read More
Warning: The Rebound May Be Over For Big Pharma
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a… Read More
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a year later. A decade later, Big Pharma’s “patent cliff” was still a key concern, and this index remained far from its previous highs. Yet in recent quarters, Big Pharma has come back with a vengeance, as shares have moved back to the levels seen all those years ago. Credit goes to several factors, most notably the absence of any new imminent blockbuster-drug patent expirations, and an industrywide focus on shareholder-friendly moves such as share… Read More
Warning: The Rebound May Be Over For Big Pharma
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a… Read More
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a year later. A decade later, Big Pharma’s “patent cliff” was still a key concern, and this index remained far from its previous highs. Yet in recent quarters, Big Pharma has come back with a vengeance, as shares have moved back to the levels seen all those years ago. Credit goes to several factors, most notably the absence of any new imminent blockbuster-drug patent expirations, and an industrywide focus on shareholder-friendly moves such as share… Read More